Table 3.
Summary of experimental data
| Spinal Injured Patients |
Organ Donors |
||||||
|---|---|---|---|---|---|---|---|
| Pt. No. | Meth | p-F-HHSiD | Dar | Pt. No. | Meth | p-F-HHSiD | Dar |
| 1 | 6.2±0.5 (M3) | 1 | 7.5±0.4 (M3) | ||||
| 2 | 7.3±0.3 (INT) | 2 | 6.1±0.2 (M3) | 6.5±0.2 (M2) | |||
| 3 | 6.2±0.2 (M3) | 7.2±0.4 (M2) | 3 | 6.5±0.2 (M2) | 7.9±0.6 (INT) | ||
| 4 | 7.7±0.5 (M3) | 4 | 6.8±0.2 (M3) | 6.3±0.1 (M2) | 8.7±0.3 (M3) | ||
| 5 | 6.9±0.3 (M2) | 5 | 6.9±0.1 (M2) | 8.3±0.2 (M3) | |||
| 6 | 7.6±0.5 (M2) | 6 | 6.8±0.2 (M2) | 8.3±0.6 (M3) | |||
| 7 | 7.7±0.3 (M2) | 7 | 8.9±0.2 (M3) | ||||
| 8 | 6.6±0.2 (M2) | 8.2±0.2 (M3) | |||||
Values are means ± 95% confidence intervals expressed as –Log (pKb or pA2). For each specimen, the affinity of the muscarinic receptor antagonists was determined as described in materials and methods for inhibiting carbachol-induced bladder contraction. The determined value was compared with the published affinity of the M2 and M3 receptors for the antagonists. If the determined affinity (95% confidence range) overlaps the range of the reported values for either subtype, the subtype within the range is shown in parenthesis after the affinity value. If the determined value (95% confidence interval) is between the reported range for the two subtypes or within the range of both subtypes, this affinity value is considered intermediate (INT) between the two subtypes. Meth, methoctramine; p-F-HHSiD, p-fluoro-hexahydrosiladifenadol; Dar, darifenacin.